会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • GPR125 AS A MARKER FOR STEM AND PROGENITOR CELLS AND METHODS USE THEREOF
    • GPR125作为干细胞和祖细胞的标记物及其使用方法
    • US20100330043A1
    • 2010-12-30
    • US12446730
    • 2007-10-23
    • Shahin RafiiSergey V. ShmelkovMarco SeandelSai H. Chavala
    • Shahin RafiiSergey V. ShmelkovMarco SeandelSai H. Chavala
    • A61K35/12C12N5/074G01N33/53A61P35/00
    • C12N5/061A61K35/12C12N5/0623C12N5/068C12N2501/11C12N2501/115C12N2501/13C12N2501/235C12N2501/998C12N2502/02C12N2502/04G01N33/56966G01N33/57492
    • The present invention relates to GPR1 25 as a marker of stem and progenitor cells, including multipotent adult spermatogonial-derived stem cells (MASCs), spermatogonial stem and progenitor cells, skin stem or progenitor cells, intestinal stem or progenitor cells, neural stem or progenitor cells, and cancer stem cells. The invention provides, inter alia, methods for enriching or isolating GPR125-positive stem or progenitor cells, methods for detecting GPR125-positive stem or progenitor cells, methods for culturing GPR125-positive stem or progenitor cells, purified GPR125-positive stem or progenitor cells, therapeutic compositions containing purified GPR125-positive stem or progenitor cells, methods for targeting therapeutic agents to GPR125-positive stem and progenitor cells, and methods of treatment comprising administering GPR125-positive stem and progenitor cells, or differentiated cells derived therefrom, to subjects in need thereof. The present invention also provides methods of detecting cancer cells based on GPR1 25 expression, and methods of targeting therapeutic agents to cancer cells to GPR125-positive cancer cells.
    • 本发明涉及GPR125作为干细胞和祖细胞的标志物,包括多能成人精原细胞来源的干细胞(MASC),精原干细胞和祖细胞,皮肤干细胞或祖细胞,肠干或祖细胞,神经干或祖细胞 细胞和癌症干细胞。 本发明尤其提供了富集或分离GPR125阳性干细胞或祖细胞的方法,用于检测GPR125阳性干细胞或祖细胞的方法,培养GPR125阳性干细胞或祖细胞,纯化的GPR125阳性干细胞或祖细胞 含有纯化的GPR125阳性干细胞或祖细胞的治疗组合物,用于将治疗剂靶向GPR125阳性干细胞和祖细胞的方法,以及治疗方法,包括将GPR125阳性干细胞和祖细胞或其衍生的分化细胞给予受试者 需要。 本发明还提供了基于GPR125表达检测癌细胞的方法,以及将治疗剂靶向癌细胞至GPR125阳性癌细胞的方法。